Stock Market News for October 1, 2026

At a glance

On October 1, 2026, Accenture reported fourth-quarter fiscal 2026 revenue of $18.7 billion; onsemi amended its merger agreement to acquire Synaptics for $5.7 billion in cash at $123 per share; NIKE reported fiscal 2027 Q1 revenue of $11.2 billion; ADARx closed additional IPO shares raising total gross proceeds of $513.2 million.

Earnings and guidance

Accenture (ACN) reported fourth-quarter results quarterly revenue of $18.7 billion, up 6% in U.S. dollars with quarterly GAAP diluted EPS of $3.29 and annual revenue of $74.2 billion for fiscal 2026.

NIKE (NKE) reported fiscal 2027 first-quarter results revenue of $11.2 billion, down 4% year over year, with net income of $712 million and diluted EPS of $0.48 for the quarter ended August 31, 2026.

Acuity (AYI) reported fiscal 2026 results fiscal fourth-quarter net sales of $1.2 billion, with diluted EPS of $5.63 and fiscal 2026 sales of $4.6 billion.

Deals and acquisitions

ON Semiconductor (ON) amended its merger agreement to acquire Synaptics in an all-cash transaction for approximately $5.7 billion at $123 per share, with Synaptics’ board unanimously supporting the amended agreement.

Nebius Group (NBIS) acquired Inferize, integrating its inference-optimization technology and team into Nebius Token Factory to shorten model cold starts and improve production inference efficiency.

Modine Manufacturing (MOD) completed spin-off and combination completed the spin-off and combination of its Performance Technologies business with Gentherm in a Reverse Morris Trust transaction valuing the business at approximately $946.4 million.

Armada Acquisition Corp. II (XRPN) shareholders approved the Evernorth business combination, with the transaction expected to raise approximately $300 million in gross cash proceeds including related private placements and trust proceeds.

TEN Holdings (XHLD) launched TEN, a digital experience platform offered via annual subscription to combine events, continuing education and audience engagement in one environment.

Financings and offerings

ADARx Pharmaceuticals (ADRX) closed exercise of underwriters' option closed sale of 3,937,500 additional IPO shares at $17.00, bringing total IPO gross proceeds to approximately $513.2 million and combined proceeds with an AbbVie private placement to about $602.5 million.

Veritone (VERI) announced equity offering entered a definitive agreement to sell 20,000,000 shares in a registered direct offering expected to generate approximately $15.0 million in gross proceeds, closing on or about October 2, 2026.

Antelope Enterprise Holdings (AEHL) announced an at-the-market equity offering program of up to $100 million with D. Boral Capital as sales agent or principal.

Phaos Technology Holdings (Cayman) (POAS) entered into securities purchase agreement secured an equity facility arrangement with High West Partners for up to US$10 million.

Clinical trials and biotech

Monte Rosa Therapeutics (GLUE) announced positive results reported MRT-8102 GFORCE-1 Phase 1 biomarker reductions with median NEK7 reductions of ~80–90%, hsCRP down 85% and lipoprotein(a) down 24%, with no serious adverse events.

AgomAb Therapeutics (AGMB) reported topline data reported positive topline results from the 48-week STENOVA open-label extension of ontunisertib in fibrostenosing Crohn’s disease with a 3% annualized disease-related event rate and no surgeries.

Shattuck Labs (STTK) announced Phase 2 trial plans to begin a randomized Phase 2 trial of SL-325 in moderate to severe hidradenitis suppurativa with an expected IND submission in October 2026 and Week 16 results in H1 2028.

Operations and regulatory

Fervo Energy Company (FRVO) declared commercial operation declared commercial operation at its Cape Station power plant on September 30, achieving 33 MW of net power production and meeting its PPA production threshold.

American Battery Technology Company (ABAT) received approval received U.S. Department of Commerce authorization to export up to $100 million of recycled black mass under a BIS license.

USA Rare Earth (USAR) completed CEO transition completed its CEO succession with Thras Moraitis assuming the CEO role and reorganized operations into Upstream, Midstream and Downstream business units.

Other notable news

Legend Biotech (LEGN) launched launched the ELITE grant program to support early-career professionals in multiple myeloma CAR-T innovation, with applications open through November 20, 2026.

SINTX Technologies (SINT) announced preliminary revenue reported preliminary Q3 revenue of $2.2 million, exceeding the high end of prior guidance and growing roughly 380% from Q2.